文献速递肿瘤 PET/CT

转移性结直肠癌缺氧患病率及其与糖酵解代谢和血管生成生物标志物的相关性

Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-10-30

本研究纳入40例转移性结直肠癌患者,行[18F]FMISO PET与[18F]FDG PET显像并检测血管生成血液标志物,随访无进展生存期。[18F]FMISO与[18F]FDG的SUVmax显著相关(p=0.003),[18F]FMISO TNR与无进展生存期(p=0.02)和总生存期(p=0.003)相关,[18F]FDG TGV与总生存期相关(p=0.02)。骨桥蛋白(而非VEGF)与两种PET参数相关。

要点

  • [18F]FMISO PET可评估转移性结直肠癌缺氧,与[18F]FDG SUVmax显著相关(p=0.003)。
  • [18F]FMISO TNR与无进展生存期(p=0.02)及总生存期(p=0.003)相关。
  • 血清骨桥蛋白与[18F]FMISO和[18F]FDG PET参数相关,VEGF不相关。

核心结论

  • 转移性结直肠癌中[18F]FMISO PET摄取与糖酵解代谢显著相关,并可预测无进展生存期和总生存期。

研究设计与样本

  • 纳入40例转移性结直肠癌患者,接受常规分期检查、[18F]FMISO PET和[18F]FDG PET显像,并采集血液标本,随访确定无进展生存期。

主要发现

  • [18F]FMISO与[18F]FDG PET的SUVmax显著相关(p=0.003)。
  • [18F]FMISO TNR与无进展生存期显著相关(p=0.02)。
  • [18F]FMISO TNR与总生存期显著相关(p=0.003)。
  • [18F]FDG TGV与总生存期显著相关(p=0.02)。
  • 血清骨桥蛋白(而非VEGF)与[18F]FMISO和[18F]FDG PET参数相关。

临床怎么用

  • 可考虑用[18F]FMISO PET评估转移性结直肠癌缺氧状态,辅助预后判断。
  • 缺氧与糖酵解代谢相关,对影响肿瘤血管生成和缺氧的新型治疗评估有潜在意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hypoxia is associated with aggressive tumour behaviour and can influence response to systemic therapy and radiotherapy. The prevalence of hypoxia in metastatic colorectal cancer is poorly understood, and the relationship of hypoxia to patient outcomes has not been clearly established. The aims of the study were to evaluate hypoxia in metastatic colorectal cancer with [18F]Fluoromisonidazole ([18F]FMISO PET) and correlate these findings with glycolytic metabolism ([18F]FDG PET) and angiogenic blood biomarkers and patient outcomes. METHODS: Patients with metastatic colorectal cancer received routine staging investigations and both [18F] FMISO PET and [18F] FDG PET scans. Correlative blood specimens were also obtained at the time of the [18F] FMISO PET scan. Patient follow-up was performed to establish progression-free survival. RESULTS: A total of 40 patients were recruited into the trial. [18F]FMISO and [18F]FDG PET scans showed a significant correlation of SUVmax (p = 0.003). A significant correlation of progression-free survival and [18F] FMISO TNR (p = 0.02) and overall survival with [18F]FMISO TNR (p = 0.003) and [18F]FDG TGV (p = 0.02) was observed. Serum levels of osteopontin, but not VEGF, correlated with [18F] FMISO and [18F]FDG PET scan parameters. CONCLUSION: [18F]FMISO PET uptake in metastatic colorectal cancer significantly correlates with glycolytic metabolism and is predictive of progression-free and overall survival. These findings have implications for the assessment and treatment of metastatic colorectal cancer patients with novel therapies which affect tumour angiogenesis and hypoxia.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lee ST, Muralidharan V, Tebbutt N, et al. Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma. Eur J Nucl Med Mol Imaging. 2020. PMID: 33125527. doi:10.1007/s00259-020-05074-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。